about
Glomerular permselectivity in early stages of overt diabetic nephropathyThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesUrinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuriaAngiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.Effect of Continuous Glucose Monitoring Accuracy on Clinicians' Retrospective Decision Making in Diabetes: A Pilot Study.Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus.Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: a longitudinal follow-up study.Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?Optimal dose of losartan for renoprotection in diabetic nephropathy.Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study.Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy.Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy.Effect of Sensor-Augmented Pump Treatment Versus Multiple Daily Injections on Albuminuria: A 1-Year Randomized Study.Treatment with continuous subcutaneous insulin infusion is associated with lower arterial stiffness.CYP2C9 variant modifies blood pressure-lowering response to losartan in Type 1 diabetic patients with nephropathyAldosterone synthase (CYP11B2)344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathyRenoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathySerum uric acid and progression of diabetic nephropathy in type 1 diabetesTubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathyRole of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathyAngiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathyACE insertion/deletion genotypes and angiotensin II receptor blockade in diabetic nephropathy: is there a light at the end of the tunnel?
P50
Q28141987-CC5B3640-A4D7-4588-BB91-528D474A8720Q28188182-688DED47-143B-4703-AD19-51BE7F2BB698Q33735287-737ECF06-E2EC-4018-AC7C-9D656131F535Q35689563-01673B0C-5F71-4B31-96F7-72D655D62871Q36340521-E71A05D8-540E-4485-B871-C77FE78DA390Q39631863-D6C592F2-4D8A-4A9D-947A-DB7BC43B938AQ41431685-D5B3FF8F-FE33-4674-B3B6-9CCB1ECA713AQ44007504-C5C85FD2-23B2-43C8-A7AD-05269C09D929Q44039629-D51C50E2-6D98-413E-B61A-9711F7421849Q44082707-AED9C89E-81B9-4484-8E56-D1B60136CDE5Q44288705-62D98775-3B1B-47F2-80E2-BA701BDE26D7Q44333371-430F9A5D-CDBE-441A-B914-DA8CAF99790EQ44378923-9E5EA59F-C872-4DBD-A8E6-2EB90FB09C4EQ44390528-4300D389-936B-4C33-863D-D120079A6F7CQ44418831-1D78E37C-627C-489B-8650-3B8212DF5C83Q44666282-75B85FF6-8F42-477B-9710-D24215C2CDFBQ45155019-CB2DA63B-26F2-44B7-89C4-F799110D3F6CQ46480458-EA340D05-3520-46D4-9817-DD614B9381C0Q46865007-DE1FFCAE-41ED-4EB0-B03B-B3F0AA1DA53EQ51713216-F00A7CAD-2D34-403A-8AB8-0830795B0817Q53427648-700FCBE7-E5FD-4E35-B878-9CC0DA4B7FDEQ59489241-998E5B50-05F8-4F16-921D-EA5B420E7273Q59489254-435EF23A-2F04-4DE2-9328-C1A4CFCC95B7Q59489271-F5CB1DA7-B825-4505-9BB1-540A67E79B09Q61948348-1929624E-E614-4929-ACD9-C5B00FCB99F3Q61948378-7A9E820D-CB50-4F47-AF1E-025569D49356Q73828659-AD0BB82B-4B5E-4C0F-933F-DB4F56744CBEQ74004634-C8FC74FE-17D1-4A07-8EE1-D261450CB3A7Q79091236-62353F99-1E1F-4349-8641-F5F396DB8A24
P50
description
medical researcher specializing in diabetes
@en
onderzoeker
@nl
հետազոտող
@hy
name
S Andersen
@ast
S Andersen
@en
S Andersen
@es
S Andersen
@nl
type
label
S Andersen
@ast
S Andersen
@en
S Andersen
@es
S Andersen
@nl
altLabel
Steen Andersen
@en
prefLabel
S Andersen
@ast
S Andersen
@en
S Andersen
@es
S Andersen
@nl
P214
P106
P214
P31
P496
0000-0002-1987-1661
P734
P7859
viaf-100520651